GlassScriptPhysician profile
Hillary S Lawrence
NPI 1528097904
$6,013.00
in general payments reported to CMS, 2019-2025
28 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.48 · 2020: $340 · 2021: $571 · 2022: $668 · 2023: $1,031 · 2024: $1,777 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,825 · Education: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.40 |
| Education | $569.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $839.67 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $669.25 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $561.60 | 2021-2025 | |
| Abbvie INC. | $479.89 | 2019-2025 | |
| Lilly USA, LLC | $419.32 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $385.33 | 2022-2025 | |
| Janssen Biotech, INC. | $357.96 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Krystal Biotech INC | $339.84 | 2023-2025 | Vyjuvek |
| Incyte Corporation | $337.37 | 2021-2025 | Opzelura |
| Ucb, INC. | $288.80 | 2020-2025 | Bimzelx |
| Leo Pharma INC. | $236.87 | 2023-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $196.94 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $176.53 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Mayne Pharma Commercial LLC | $76.04 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.42 | 2020-2023 | Jublia |
| Organon LLC | $69.59 | 2025 | Vtama |
| Avanos Medical | $68.88 | 2022 | |
| Galderma Laboratories, L.P. | $68.40 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $60.70 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $40.60 | 2023-2024 | Ycanth |
| Amgen INC. | $31.16 | 2023-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.32 | 2022-2024 | Spevigo |
| Chiesi USA, INC. | $30.14 | 2024 | Filsuvez |
| Pierre Fabre Pharmaceuticals, INC. | $29.55 | 2025 | Hemangeol |
| Blueprint Medicines Corporation | $23.44 | 2025 | Ayvakit |
| Aclaris Therapeutics, INC. | $22.86 | 2019 | |
| Amryt Pharma Holdings LTD | $19.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.